ATOS - Atossa Genetics Inc

ATOS - Atossa Genetics Inc

https://www.atossatherapeutics.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Excelerate Energy ( NYSE:EE ) , Atossa Therapeutics ( NASDAQ:ATOS )

Benzinga • 3 months, 1 week ago • score: 0.25

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - Atossa Therapeutics ( NASDAQ:ATOS )

Benzinga • 5 months, 3 weeks ago • score: 0.36

SEATTLE, March 20, 2025 ( GLOBE NEWSWIRE ) -- Atossa Therapeutics, Inc. ATOS ( "Atossa" or the "Company" ) , a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on ...

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire • 5 months, 3 weeks ago • score: 0.38

Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time ...

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

GlobeNewswire • 7 months, 1 week ago • score: 0.51

SEATTLE, Feb. 05, 2025 ( GLOBE NEWSWIRE ) -- Atossa Therapeutics, Inc. ( Nasdaq: ATOS ) ( "Atossa" or the "Company" ) , a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulations to Dr. Tessa Cigler, esteemed Board ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington.

52W High

$1.66

52W Low

$0.55

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.10

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

2.01

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.76

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.07%

Institutions (25–75% balanced)

21.17%

Shares Outstanding

129,171,000

Float

129,100,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-0.22

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.42%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0014

Previous

-0.0028

Trend

Rising

Signal Cross

Crossed Up Today

As of

Sep. 11, 2025